FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.

ABSTRACT: PET using ¹⁸F-FDG for treatment monitoring in patients with lymphoma is one of the most well-developed clinical applications. PET/CT is nowadays used during treatment to assess chemosensitivity, with response-adapted therapy given according to 'interim' PET in clinical practice to adults and children with Hodgkin lymphoma. PET is also used to assess remission from disease and to predict prognosis in the pretransplant setting. Mature data have been reported for the common subtypes of aggressive B-cell lymphomas, with more recent data also supporting the use of PET for response assessment in T-cell lymphomas. The Deauville five-point scale incorporating the Deauville criteria (DC) is recommended for response assessment in international guidelines. FDG uptake is graded in relation

SUBMITTER: Barrington SF 

PROVIDER: S-EPMC5541086 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature